



FOR IMMEDIATE RELEASE
Tuesday, November 6, 2001

CONTACT: Dr. Floyd E. Bloom
Chief Executive Officer
(858) 677-0466

**NEUROME, INC. ANNOUNCES DR. TOMAS HÖKFELT AS FIRST
SCIENTIFIC ADVISORY BOARD MEMBER**

LA JOLLA, CA – Neurome, Inc. announced today the appointment of Tomas Hökfelt, M.D., Ph.D., as the first member of its Scientific Advisory Board. Dr. Hökfelt, a Professor in the Department of Neuroscience at Karolinska Institutet in Stockholm, Sweden, is a world leader in the mapping of chemical components in neurotransmission in the brain.

“Tomas Hökfelt is not only an innovator, but he was the first to notice the coexistence of families of neurotransmitters in the same neuron, breaking a long held concept of how neurons communicate with each other,” said Dr. Floyd Bloom, Neurome’s chief executive officer. “His theories of chemical communication in the brain will be critical to apply to the discoveries that our company hopes to make.”

Throughout his career, Dr. Hökfelt has focused his research on areas associated with the localization of neurotransmitters and other messengers in the nervous system, using histochemical techniques. His current projects center around the possibility that neurons produce and release more than one messenger at synapses, while simultaneously understanding the implications of such coexistence of multiple messengers.

“Neurome’s remarkable progress in the industrialization of neuroanatomy provides us with a preview of the future of neuroscience, and I am excited to join the Neurome science team in this promising work,” commented Hökfelt.

Born in Stockholm in 1940, and raised in Sweden and Germany, Dr. Hökfelt pursued his undergraduate medical studies at Karolinska Institutet, where he also earned his Ph.D. and M.D. In 1969, he was appointed Assistant Professor at the Swedish Medical Research Council. In 1979, Dr. Hökfelt became Professor in Histology with Cell Biology at Karolinska Institutet and he served as the vice chairman of its Department of Neuroscience at the Institutet from 1993-1999.

Presenter of over 40 plenary and keynote lectures at distinguished universities and institutions, Dr. Hökfelt has edited many books/handbook volumes related to neuroscience, and has served on the editorial boards of numerous journals including *Neuroscience*, *Brain Research*, *Peptides*, *Science*, and *Experimental Brain Research*.

Dr. Hökfelt is the recipient of over 15 major awards for his neuroscience research, including two awards from the Royal Academy of Sciences, Stockholm (1978 and 1979), The New York Academy of Sciences Award in Biological and Medical Sciences (1985), the Artois-Baillet Latour Health Prize (1987), The Bristol-Myers Award for Distinguished Achievement in Neuroscience Research (1988), Anders Jahre's Prize (1990), and The Eli Lilly Preclinical Research Award (1991).

Dr. Hökfelt is a Member of the National Academy of Sciences (USA), and has been named Fogarty International Scholar at the National Institutes of Health (Bethesda, Maryland), Associate of Neuroscience Research Program (Boston and New York), Honorary Member of the American Physiological Society, and Honorary Member of the Centre for Neuroscience, University College (London). Additionally, he is a Member of the International Scientific Programme Committee for the Sixth IBRO World Congress of Neuroscience, Member and Chairman of the Committee of the Dargut and Milena Kemali Foundation, Member of the Nobel Assembly, and Member of the Advisory Board of the Institute of Neuroscience of the Chinese Academy of Sciences in Shanghai.

Neurome, Inc. develops standardized, quantitative databases that accurately depict and integrate gene expression patterns in the three-dimensional context of the brain's structures, circuits and cells, and deploys these databases in primary research directed toward the discovery and development of gene targets for enhancement of brain function and treatment of brain-based disease. Neurome performs contract brain research for pharmaceutical and biotechnology companies, while at the same time pursuing its own in-house and collaborative research protocols. The data collected from these efforts will populate an evolving, comprehensive database available by subscription and useful on a broad level for analyses of mouse models of brain function and disease. In this regard, the application of the Neurome technologies will provide rigorous, quantitative data that are optimally suited to the measurement of subtle cell-type specific shifts in gene expression, as well as progression and prevention of degenerative events affecting specific cell classes and brain regions.

For more information, please contact Neurome, Inc., 11149 North Torrey Pines Road, La Jolla, California 92037-1031. Telephone: (858) 677-0466; Fax (858) 677-0458; Web site: www.neurome.com.

###